Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$GILD Maxim Group Maintains Buy On Gilead On The Heels Of New Drug Application In Japan http://www.smarteranalyst.com/2014/09/24/maxim-group-maintains-buy-gilead-heels-new-drug-application-japsn/
$GILD Maxim Group Maintains Buy On Gilead On The Heels Of New Drug Application In Japan http://www.smarteranalyst.com/2014/09/24/maxim-group-maintains-buy-gilead-heels-new-drug-application-japsn/
$BBBY Oppenheimer Maintains Market Perform On Bed Bath Following Earnings Release http://www.smarteranalyst.com/2014/09/24/oppenheimer-maintains-market-perform-bed-bath-following-earnings-release/
$BBBY Oppenheimer Maintains Market Perform On Bed Bath Following Earnings Release http://www.smarteranalyst.com/2014/09/24/oppenheimer-maintains-market-perform-bed-bath-following-earnings-release/
$GLMD Maxim Assigns Buy On Galmed Pharmaceuticals Following The Award Of Fast Track Designation http://www.smarteranalyst.com/2014/09/23/maxim-assigns-buy-galmed-pharmaceuticals-following-award-fast-track-designation/
$GLMD Maxim Assigns Buy On Galmed Pharmaceuticals Following The Award Of Fast Track Designation http://www.smarteranalyst.com/2014/09/23/maxim-assigns-buy-galmed-pharmaceuticals-following-award-fast-track-designation/
$THLD Threshold: We Regard The IDMC Green Light Positively, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/23/threshold-regard-idmc-green-light-positively-says-h-c-wainwright/
$THLD Threshold: We Regard The IDMC Green Light Positively, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/23/threshold-regard-idmc-green-light-positively-says-h-c-wainwright/
H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS http://www.smarteranalyst.com/2014/09/23/h-c-wainwright-comments-neuralstem-following-presentation-annual-symposium-als/
$INO Maxim Group Reiterates Buy On Inovio Pharmaceuticals Following Initiation Plans For Phase 1 Study http://www.smarteranalyst.com/2014/09/23/maxim-group-reiterates-buy-inovio-pharmaceuticals-following-initiation-plans-phase-1-study/
Maxim Group Reiterates Buy On Inovio Pharmaceuticals Following Initiation Plans For Phase 1 Study http://www.smarteranalyst.com/2014/09/23/maxim-group-reiterates-buy-inovio-pharmaceuticals-following-initiation-plans-phase-1-study/
$PGNX Brean Capital Reiterates Buy On Progenics Following Azedra Phase 2 Data http://www.smarteranalyst.com/2014/09/23/brean-capital-reiterates-buy-progenics-following-azedra-phase-2-data/
$SLXP Cantor Fitzgerald Reiterates Buy On Salix Pharma, Increases PT To $181 http://t.co/WgMomIv6Va
$SLXP Cantor Fitzgerald Reiterates Buy On Salix Pharma, Increases PT To $181 http://t.co/WgMomIv6Va
$EXPE Cantor Fitzgerald Remains Bullish On Expedia Following Solid Growth In July And August
http://t.co/jWsl2mpI3F
$EVOK Evoke Pharma: To Us, The Stock Now Looks Even More Undervalued, Says Cantor Fitzgerald
http://t.co/MjYTLQ9ngw
$EVOK Evoke Pharma: To Us, The Stock Now Looks Even More Undervalued, Says Cantor Fitzgerald
http://t.co/MjYTLQ9ngw
$IMMR Feltl and Company Reiterates Buy On Immersion Shares, $12 PT http://www.smarteranalyst.com/2014/09/23/feltl-company-reiterates-buy-immersion-shares-12-pt/
$RXN Oppenheimer Initiates Outperform On Rexnord; Sees 20% For The Stock http://www.smarteranalyst.com/2014/09/23/oppenheimer-initiates-outperform-rexnord-sees-2o-stock/
$ZINC Oppenheimer Reiterates Outperform On Horsehead Holding; Sees 74% Upside For The Stock http://www.smarteranalyst.com/2014/09/23/oppenheimer-reiterates-outperform-horsehead-holding-sees-74-upside-stock/
$BDBD Oppenheimer Reiterates Outperform On Boulder Brands Following Natural Products Expo East Conference http://www.smarteranalyst.com/2014/09/23/oppenheimer-reiterates-outperform-boulder-brands-following-natural-products-expo-east-conference/
$BDBD Oppenheimer Reiterates Outperform On Boulder Brands Following Natural Products Expo East Conference http://www.smarteranalyst.com/2014/09/23/oppenheimer-reiterates-outperform-boulder-brands-following-natural-products-expo-east-conference/
$CHE Oppenheimer Remains Bullish On Chemed Following Meetings With Management; Raises PT To $115 http://www.smarteranalyst.com/2014/09/23/oppenheimer-remains-bullish-chemed-following-meetings-management-raises-pt-115/
$CHE Oppenheimer Remains Bullish On Chemed Following Meetings With Management; Raises PT To $115 http://www.smarteranalyst.com/2014/09/23/oppenheimer-remains-bullish-chemed-following-meetings-management-raises-pt-115/
$ASNA Oppenheimer Maintains Outperform On Ascena Retail, Reduces PT To $19 http://www.smarteranalyst.com/2014/09/23/oppenheimer-maintains-outperform-ascena-retail-reduces-pt-19/
$THLD Cowen Reiterates Outperform On Threshold On The Back Of IDMC Recommendation http://www.smarteranalyst.com/2014/09/22/cowen-reiterates-outperform-threshold-back-idmc-recommendation/
Here's another one from today.
$DXCM William Blair Assigns Outperform On Dexcom Shares http://www.smarteranalyst.com/2014/09/22/william-blair-assigns-outperform-dexcom-shares/
$PETX Aratana: Public Offering Eliminates Financial Overhang, Says William Blair http://www.smarteranalyst.com/2014/09/22/aratana-public-offering-eliminates-financial-overhang-says-william-blair/
$DVAX William Blair Reiterates Outperform On Dynavax Following Completion Of Enrollment In HBV-23 http://www.smarteranalyst.com/2014/09/22/william-blair-reiterates-outperform-dynavax-following-completion-enrollment-hbv-23/
William Blair Reiterates Outperform On Dynavax Following Completion Of Enrollment In HBV-23 http://www.smarteranalyst.com/2014/09/22/william-blair-reiterates-outperform-dynavax-following-completion-enrollment-hbv-23/
$YHOO Oppenheimer Maintains Buy On Yahoo!; Raises Price Target To $48 On Alibaba Public Valuation http://www.smarteranalyst.com/2014/09/22/oppenheimer-maintains-buy-yahoo-raises-price-target-48-alibaba-public-valuation/
Oppenheimer Maintains Buy On Yahoo!; Raises Price Target To $48 On Alibaba Public Valuation http://www.smarteranalyst.com/2014/09/22/oppenheimer-maintains-buy-yahoo-raises-price-target-48-alibaba-public-valuation/
$OXGN H.C. Wainwright Reiterates Buy On Oxigene Following Initiation Of Phase 2 Study http://www.smarteranalyst.com/2014/09/22/h-c-wainwright-reiterates-buy-oxigene-following-initiation-phase-2-study/
$SRPT Roth Capital Comments On Sarepta As Pivotal Study Dosing Delayed http://www.smarteranalyst.com/2014/09/22/roth-capital-comments-sarepta-pivotal-study-dosing-delayed/
$ADHD Roth Capital Reiterates Buy On Alcobra Following The Completion Of Phase III Clinical Trial of MDX http://www.smarteranalyst.com/2014/09/22/roth-capital-reiterates-buy-alcobra-following-completion-phase-iii-clinical-trial-mdx/
$ADHD Roth Capital Reiterates Buy On Alcobra Following The Completion Of Phase III Clinical Trial of MDX http://www.smarteranalyst.com/2014/09/22/roth-capital-reiterates-buy-alcobra-following-completion-phase-iii-clinical-trial-mdx/
$BLUE Roth Capital Initiates Buy On Bluebird Bio; Sees 38% Upside For The Stock http://www.smarteranalyst.com/2014/09/22/roth-capital-initiates-buy-bluebird-bio-sees-38-upside-stock/
$FINL Sterne Agee Sets Expectations On Finish Line; Maintains Neutral Stance http://www.smarteranalyst.com/2014/09/22/sterne-agee-sets-expectations-finish-line-maintains-neutral-stance/
$NKE: Brand Is Well Positioned But Strong USD Should Modestly Hamper Revenue Growth, Says Sterne Agee http://www.smarteranalyst.com/2014/09/22/nike-brand-well-positioned-strong-usd-modestly-hamper-revenue-growth-says-sterne-agee/
$NPSP NPS Pharma: Rems Concern? Overblown, Says Canaccord http://www.smarteranalyst.com/2014/09/19/nps-pharma-rems-concern-overblown-says-canaccord/